Clinical Trial ConcernsInvestors are cautious due to the ongoing clinical hold, which needs to be resolved before deucrictibant can receive full credit for the CHAPTER-1 data.
Competitive LandscapePotential volatility in PHVS shares expected with competitor's trial data release, highlighting market sensitivity to competitive developments.
Drug Efficacy DoubtsSome inconsistencies in the data suggest that while sebetralstat is effective, a significant portion of patients required a second dose, and not all attacks were resolved within 24 hours.